PHARMACOLOGICAL MANAGEMENT OF IRON DEFECIENCY ANEMIA

Murzaeva Mariia.I., Senior lecturer , Department of Clinical pharmacology and pathology, Osh State university. ORCID :- https://orcid.org/0009-0000-7957-9366 KRISHNASAMY GOUNDER AYYASWAMI THAMARAI KRISHNAN, 4th year Student, Osh State UniversityInternational Medical Faculty. PHARMACOLOGICAL MANAGEMENMT OF IRON DEFICIENCY ANEMIA ABSTRACT :- The most prevalent nutritional condition in the world is iron deficiency anemia (IDA), which is caused by insufficient iron intake, absorption, or chronic loss and impairs hemoglobin synthesis. Fatigue, pallor, dyspnea, and laboratory evidence of microcytic hypochromic anemia with low serum ferritin and transferrin saturation are some of the clinical manifestations. Parenteral iron is only used in cases of severe anemia, intolerance, or malabsorption; oral iron supplements, such as ferrous sulfate, are the first-line treatment. Monitoring hemoglobin and iron indices is crucial to determine response, and adjunctive therapy with folic acid or vitamin B12 may be required in cases of coexisting deficiencies. Improved tolerability and bioavailability are provided by novel formulations such as liposomal and sucrosomial iron, which emphasize customized treatment to replenish iron stores and enhance patient. Keywords:-Etiology, pathophysiology, Treatment and guidelines, Iron Supplementation. INTRODUCTION :- One-fourth of the world's population suffers from anemia, which contributes 8.8% of the total disease burden worldwide. The most common cause of anemia in both sexes and across nations is iron deficiency, with women more likely to suffer from it. Anemia is more common in hospital settings and as people age. Anemia raises medical expenses and reduces one's ability to work. A lack of iron can also lead to infertility, fatigue, poor quality of life, restless legs syndrome (RLS), and cognitive decline. Iron therapy can reverse these symptoms even if anemia is not present. Anemia and iron deficiency are made more likely by gastrointestinal disorders like celiac disease and inflammatory bowel disease (IBD), chronic kidney disease (CKD), cancer, and chronic heart failure (CHF). Iron deficiency can also affect the clinical outcome. Regardless of hemoglobin (Hb) level, iron deficiency is linked to a higher risk of death in CHF.Additionally linked to reactive thrombocytosis, iron deficiency may raise the risk of thromboembolic events. Etiology :- The cause of iron-deficiency anemia varies based on age, gender, and socioeconomic status. Iron deficiency may result from insufficient iron intake, decreased absorption, or blood loss. Irondeficiency anemia is most often from blood loss, especially in older patients. It may also be seen with low dietary intake, increased systemic requirements for iron such as in pregnancy, and decreased iron absorption such as in celiac disease. In neonates, breastfeeding is protective against iron deficiency due to the higher bioavailability of iron in breast milk compared to cow’s milk; iron deficiency anemia is the most common form of anemia in young children on cow’s milk. In developing countries, a parasitic infestation is also a significant cause of iron-deficiency anemia. Dietary sources of iron are green vegetables, red meat, and iron-fortified milk formulas Pathophysiology :- There are multiple ways that iron-restricted erythropoiesis causes anemia. Depleted iron stores in cases of pure iron deficiency result from an imbalance between iron uptake and utilization. Initially, iron recycling from erythrocyte turnover may prevent anemia. However, patients may have symptoms without anemia because iron deficiency alone is linked to fatigue and RLS. Hypochromic anemia and microcytic anemia are caused by a persistently negative balance. Resolution results from adequate iron replacement and treatment of the underlying cause of iron deficiency. There are multiple ways that iron-restricted erythropoiesis causes anemia. Depleted iron stores in cases of pure iron deficiency result from an imbalance between iron uptake and utilization. Initially, iron recycling from erythrocyte turnover may prevent anemia. However, patients may have symptoms without anemia because iron deficiency alone is linked to fatigue and RLS. Hypochromic anemia and microcytic anemia are caused by a persistently negative balance. Resolution results from adequate iron replacement and treatment of the underlying cause of iron deficiency. Assessment and Diagnosis:- A blood hemoglobin level below 130 g/L for men and 120 g/L for women is considered anemia, according to the WHO. Serum ferritin, the molecule that stores iron, should be less than 30 ug/L in cases of isolated iron deficiency. On the other hand, ferritin is an acute phase protein that can rise when inflammation is present. Therefore, ferritin levels below 100 ug/L are suggestive of IDA if there is concurrent inflammation evidence, such as elevated C-reactive protein. The iron transporter transferrin is typically elevated, but because it is a negative acute phase protein, it can be normal or decreased in chronic inflammatory conditions. There will be a decrease in serum iron and transferrin saturations (TSAT), which must be less than 20% in order to diagnose IDA. The breakdown of IDA diagnostic criteria is shown in table 1. Because a considerable amount of iron must be lost before the Hb levels start to drop, it is important to remember that iron deficiency should not be ruled out in the presence of a normal Hb. Therefore, mild iron deficiency without anemia is indicated by a low mean corpuscular hemoglobin with a normal hemoglobin or an increase in the width of the red cell distribution. TREATMENT:- In order to provide timely guidance on a topic of high clinical importance to the AGA membership, the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board commissioned and approved this expert review. It was subjected to both internal peer review by the CPUC and external peer review using the standard protocols of Clinical Gastroenterology and Hepatology. Expert opinion and a review of the published literature served as the basis for these Best Practice Advice (BPA) statements. These BPA statements lack formal ratings pertaining to the strength of the arguments put forth or the quality of the evidence because systematic reviews were not conducted. Guidelines for Treatment:- • There are no benefits to using one oral iron formulation over another. The least expensive iron formulation is ferrous sulfate. • Give iron orally no more than once a day. Some patients with comparable or equal rates of iron absorption may tolerate iron dosing every other day better than daily dosing. • To enhance absorption, include vitamin C in oral iron supplements. • If a patient cannot tolerate oral iron, if a trial of oral iron does not raise ferritin levels, or if the patient has a condition that makes oral iron absorption unlikely, intravenous iron should be used. • It is preferable to use intravenous iron formulations that can replenish iron deficiencies with one or two infusions rather than ones that need more than two. • True anaphylaxis is extremely uncommon; the risks associated with all intravenous iron formulations are similar. The great majority of intravenous iron reactions are pseudo-allergies related to complement activation (infusion reactions) and should be handled as such. • Iron-deficiency anemia with no known cause of chronic gastrointestinal blood loss should be treated with intravenous iron therapy in patients who have had bariatric procedures, especially those that may interfere with normal duodenal iron absorption. • Clinicians should first ascertain whether iron-deficiency anemia in patients with inflammatory bowel disease is caused by insufficient iron intake or absorption or by iron loss, usually from gastrointestinal bleeding. Effective treatment of active inflammation is necessary to improve iron absorption or lessen iron deficiency. • People with iron-deficiency anemia, inflammatory bowel disease, and active inflammation with impaired absorption should receive intravenous iron therapy. • To restore iron stores in patients with portal hypertensive gastropathy and irondeficiency anemia, oral iron supplements should be used first. When oral iron therapy is ineffective for patients with persistent bleeding, intravenous iron therapy should be used. • Nonselective β-blockers may be used to treat portal hypertension in patients with iron-deficiency anemia and portal hypertensive gastropathy who do not have another known cause of chronic blood loss. • Consider endoscopic therapy with endoscopic band ligation or thermal techniques like argon plasma coagulation for patients with iron-deficiency anemia due to gastric antral vascular ectasia who do not respond well to iron replacement. • To enhance iron absorption, make sure patients with celiac disease and irondeficiency anemia follow a gluten-free diet. Depending on the patient’s tolerance and the degree of iron deficiency, consider oral iron supplements. If iron stores do not improve, consider intravenous iron therapy. • To enhance iron absorption, make sure patients with celiac disease and irondeficiency anemia follow a gluten-free diet. Depending on the patient's tolerance and the degree of iron deficiency, consider oral iron supplements. If iron stores do not improve, consider intravenous iron therapy. • Iron replacement therapy should be used in conjunction with endoscopic treatment for angioectasias. When iron replacement and endoscopic therapy fail to resolve refractory small-bowel angioectasias, medical therapy should be saved for compassionate treatment. IRON SUPPLEMENTATION :- Indication:- For iron-deficient states resulting from iron deficiency anemia, iron deficiency without anemia, nutritional deficiencies, malabsorption, chronic inflammatory conditions, blood loss, or an increase in the body’s iron requirements, iron supplements are recommended. For overall health, iron is a necessary mineral. Anemia is the result of the body producing less hemoglobin and circulating erythrocytes due to depleted iron stores. Fatigue, weakness, dyspnea, pica and pagophagia, tachycardia, altered mental status, hypothermia, and an elevated risk of infection are all signs of iron deficiency. Restoring the body’s iron reserves and relieving symptoms are the main goals of treatment. If treatment is not received, this could result in negative outcomes for expectant mothers and children, including neurodevelopmental delays. Women of childbearing age are at risk because anemia is frequently brought on by pregnancy and monthly menstruation. Iron-deficient diets and indolent gastrointestinal blood loss due to gastritis or underlying cancer are more common in the elderly. Iron deficiency frequently prevents patients with chronic kidney disease or hemodialysis from stimulating their kidneys to produce erythropoietin, which exacerbates anemia. Some people may be unable to properly digest the iron in their diets due to malabsorptive states (e.g., pernicious anemia, small intestinal bacterial overgrowth (SIBO), celiac disease, or Whipple disease). Administration :- Oral iron supplementation:- • With ferrous fumarate (33 percent elemental iron), ferrous gluconate (12 percent elemental iron), and ferrous sulfate (20 percent elemental iron), oral iron replacement therapy is the most affordable and accessible option for the general public. • Iron should be taken at least half an hour before meals or two hours before taking other medications for optimal absorption. • The patient may take it with small meals if they are unable to handle the gastrointestinal side effects. • Steer clear of milk, calcium, antacids, high-fiber foods, and caffeine when taking it. • To enhance absorption, some research has recommended taking iron with vitamin C supplements or orange juice. IV Iron Supplementation :- IV infusion is a substitute for oral iron supplementation and might be better for patients who: • Unable to handle oral iron because of adverse effects Women who are already experiencing severe nausea and vomiting during pregnancy • Iron absorption is hampered in gastric bypass patients by decreased gastric secretion. • Individuals with malabsorption disorders (e.g., SIBO, celiac disease, Whipple’s disease, or pernicious anemia) that hinder proper absorption into the body • Hepcidin levels are higher in people with chronic inflammatory conditions like rheumatoid arthritis or SLE, which lowers oral iron absorption. Although IM iron is available, it is not recommended because patients may experience severe injection site pain and uneven absorption. It might discolor the skin as well. Adverse effects Constipation or diarrhea, flatulence, metallic taste, tooth discoloration, nausea or vomiting, and epigastric distress are among the most frequent gastrointestinal side effects. The shift to green or “tarry black” stool color and caliber may cause discomfort for patients. Compared to IV iron or a placebo, many oral iron supplements (such as ferrous fumarate, ferrous gluconate, and ferrous sulfaiated) have more gastrointestinal side effects. By taking iron supplements on a modified schedule (three times a week instead of daily) or with food, patients can lessen the negative effects; however, this may reduce absorption and make it less convenient for the patient, which could result in non-compliance. Anaphylaxis and infusion reactions are possible side effects of intravenous iron. By creating an insoluble complex with other drugs, iron may reduce their absorption. These consist of tetracyclines, penicillin, fluoroquinolones, and methyldopa/levodopa. CONCLUSION:- A common hematologic condition called iron deficiency anemia (IDA) is brought on by the body not having enough iron to meet its physiological needs. Restoring iron stores through pharmacological interventions is the cornerstone of managing IDA. The effectiveness and affordability of oral iron supplements, especially ferrous salts like ferrous sulfate, make them widely used. However, patient adherence is frequently restricted by gastrointestinal side effects. Novel oral formulations, like ferric maltol and sucrosomial iron, have been developed recently and offer better absorption profiles and gastrointestinal tolerability. Iron deficiency anemia (IDA) is a common hematologic condition caused by the body not having enough iron to meet its physiological needs. The mainstay of IDA treatment is pharmacological interventions that restore iron stores. Oral iron supplements, particularly ferrous salts like ferrous sulfate, are popular due to their affordability and efficacy. However, gastrointestinal side effects often limit patient adherence. Recently, new oral formulations have been created that provide improved gastrointestinal tolerability and absorption profiles, such as ferric maltol and sucrosomial iron. REFERANCE:- 1. Jimenez, K., Kulnigg-Dabsch, S. & Gasche, C., 2015. Management of iron deficiency anemia. Gastroenterology & Hepatology (New York), 11(4), pp.241–250. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4836595/. 2. National Institutes of Health, 2017. Iron Deficiency Anemia. In: Iron Deficiency Anemia: A Guide for the Primary Care Physician. Available at: https://www.ncbi.nlm.nih.gov/books/NBK448065/. 3. Jiménez, K., Kulnigg-Dabsch, S. & Gasche, C., 2015. Management of iron deficiency anemia. Gastroenterology & Hepatology (New York), 11(4), pp.241–250. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4836595/. 4. Pantopoulos, K., 2024. Oral iron supplementation: new formulations, old questions. Haematologica, 109(9), pp.2790–2801. Available at: https://doi.org/10.3324/haematol.2024.284967. 5. Kolarš, B., Mijatović Jovin, V., Živanović, N., Minaković, I., Gvozdenović, N., Dickov Kokeza, I. & Lesjak, M., 2025. Iron deficiency and iron deficiency anemia: A comprehensive overview of established and emerging concepts. Pharmaceuticals, 18(8), 1104. Available at: https://www.mdpi.com/1424-8247/18/8/1104. 6. Kolarš, B., Mijatović Jovin, V., Živanović, N., Minaković, I., Gvozdenović, N., Dickov Kokeza, I. & Lesjak, M., 2025. Iron deficiency and iron deficiency anemia: A comprehensive overview of established and emerging concepts. Pharmaceuticals, 18(8), p.1104. Available at: https://doi.org/10.3390/ph18081104.